Kavar Capital Partners Group LLC Sells 154 Shares of Novo Nordisk A/S (NYSE:NVO)

Kavar Capital Partners Group LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 31,599 shares of the company’s stock after selling 154 shares during the period. Kavar Capital Partners Group LLC’s holdings in Novo Nordisk A/S were worth $2,718,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. International Assets Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $98,765,000. Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $42,017,000. Sanctuary Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $41,646,000. Finally, World Investment Advisors LLC increased its position in shares of Novo Nordisk A/S by 2,655.9% during the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after acquiring an additional 270,234 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $87.94 on Monday. The firm has a market capitalization of $394.65 billion, a PE ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $95.35 and a two-hundred day moving average price of $114.80. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.